本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/18，由董事长提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 30 4 | 4 | 日~2026 | 年 | 月 | 日 29 | | 预计回购金额 | 20,000万元~30,000万元 | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 433.40万股 | | | | | | | 累计已回购股数占总股本比例 | 0.20% | | | | | | | 累计已回购金额 | 9,681.15万元 | | | | | | | 实际回购价格区间 | 20.75元/股~24.25元/股 | | | | | | 一、 回购股份的基本情况 证券代码：600 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600426 证券简称：华鲁恒升 编号：临 2025-051 山东华鲁恒升化工股份有限公司 关于停车检修生产装置复产的公告 山东华鲁恒升化工股份有限公司董事会 山东华鲁恒升化工股份有限公司（以下简称 "公司"）于 2025 年 7 月 31 日披露了《关于部分生产装置停车检修的公告》 (临 2025- 040 号)，根据年度计划，公司于 2025 年 8 月 2 日开始对部分生产装置 进行停车检修。 2025 年 9 月 2 日 至 2025 年 8 月 31 日，公司检修工作已经完成，恢复正常生产。 特此公告。 ...

格隆汇9月1日丨华鲁恒升(600426.SH)公布，截至2025年8月31日，公司已累计回购股份433.40万股，占 公司总股本的比例为0.20%，回购成交的最高价为24.25元/股、最低价为20.75元/股，支付的资金总额为 人民币9,681.15万元（不含交易费用）。 ...

华鲁恒升（600426）(600426.SH)发布公告，根据年度计划，公司于2025年8月2日开始对部分生产装置 进行停车检修。至2025年8月31日，公司检修工作已经完成，恢复正常生产。 ...

智通财经APP讯，华鲁恒升(600426.SH)发布公告，根据年度计划，公司于2025年8月2日开始对部分生 产装置进行停车检修。至2025年8月31日，公司检修工作已经完成，恢复正常生产。 ...

华鲁恒升公告，根据年度计划，公司于2025年8月2日开始对部分生产装置进行停车检修。至2025年8月 31日，公司检修工作已经完成，恢复正常生产。 ...

社保基金持有期限最长的个股是华鲁恒升，自2012年四季度以来已累计持有51个季度，最新全国社保基 金一零六组合、全国社保基金一零三组合、全国社保基金一一四组合、全国社保基金四零一组合，位列 公司第三大、第四大、第七大、第十大流通股东，持股量合计为1.33亿股，占流通股比例为6.26%，社 保基金持有期限较长的还有中原传媒、我武生物、扬农化工等，已连续持有44、43、43个季度。 社保基金连续持仓超5年的46只个股中，从二季度末社保基金持股量来看，常熟银行、南山铝业、太阳 纸业等持股数量居前，社保基金分别持有2.06亿股、1.60亿股、1.51亿股。社保基金持股比例居前的有 科锐国际、华鲁恒升、常熟银行等，持股比例分别为6.30%、6.26%、6.23%。 财报季，机构持股动向逐渐浮出水面，社保基金二季度末共现身525只股，其中，46股已连续持有超20 个季度。 作为风格稳健的长期机构投资者，社保基金长线持有的重仓股引人关注，据证券时报·数据宝统计，截 至9月1日，公布半年报公司中，社保基金最新出现在525家公司前十大流通股东榜，向前追溯发现，共 有258只股获社保基金连续持有4个季度以上。其中，160只社保基 ...

证 券 研 究 报 告 华鲁恒升（600426）2025 年中报点评 强推（维持） 邮箱：yanghui@hcyjs.com 执业编号：S0360522050001 Q2 业绩环比修复，技改升级+新材料新项目 助力长期成长 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 34,226 | 35,765 | 38,608 | 40,910 | | 同比增速(%) | 25.6% | 4.5% | 8.0% | 6.0% | | 归母净利润(百万) | 3,903 | 3,510 | 4,167 | 4,739 | | 同比增速(%) | 9.1% | -10.1% | 18.7% | 13.7% | | 每股盈利(元) | 1.84 | 1.65 | 1.96 | 2.23 | | 市盈率(倍) | 15 | 16.2 | 13.6 | 12.0 | | 市净率(倍) | 1.8 | 1.7 | 1.6 | 1.4 | 资料来源：公司公告 ...

Core Insights - The report emphasizes that the chemical industry is entering a new phase of capital expenditure, with a focus on the rebalancing of supply and demand following the release of production capacity during the 14th Five-Year Plan period [2][6] - The report indicates that the bottom of the cycle is becoming clearer, with potential price increases for chemical products driven by demand recovery and supply stability in the second half of the year [2][6] Industry Overview - The current cycle has reached its tail end, with a total of 12 quarters of decline since Q3 2022, following a 7-quarter expansion from Q4 2020 to Q2 2022 [10][12] - The report outlines that the chemical industry has experienced three significant price fluctuation cycles since 2010, with the latest cycle characterized by a demand-driven recovery followed by a supply-side pressure [8][10] Investment Recommendations - The report suggests focusing on sectors with relatively low valuations, such as sucralose (recommended: Jinhe Industrial), pesticides (recommended: Yangnong Chemical, Runfeng Shares), and MDI (recommended: Wanhua Chemical) [3][4] - It highlights the importance of domestic demand in countering tariff impacts, recommending companies in refrigerants and fertilizers [3][4] - The report identifies investment opportunities in sectors with upcoming capacity releases, such as organic silicon (recommended: Xin'an Chemical) and spandex [3][4] Price and Profitability Trends - The report notes that many sub-industry product prices remain at historical lows, with specific prices for spandex, PA6, and other fibers at 0%, 4%, and 5% of historical levels respectively [28] - It mentions that the chemical industry has seen a slight recovery in profitability in Q1 2025, although the overall performance remains under pressure [27][25] Supply and Demand Dynamics - The report indicates that the global chemical capital expenditure is on a downward trend, with domestic companies experiencing a slowdown in investment while still facing significant pressure to convert projects into fixed assets [22][32] - It also states that both domestic and international markets are entering a replenishment phase in 2025, which may influence inventory levels and pricing strategies [35][36]

Group 1 - Tianqi Materials reported a revenue of 7.03 billion yuan for the first half of 2025, a year-on-year increase of 28.97% [2][3] - The net profit attributable to shareholders was 268 million yuan, up 12.79% year-on-year, while the net profit excluding non-recurring items was 235 million yuan, reflecting a growth of 26.01% [2][3] - Basic earnings per share increased to 0.14 yuan, a rise of 16.67% compared to the previous year [3] Group 2 - New Zobang achieved a revenue of 4.25 billion yuan, marking an 18.58% increase year-on-year, with a net profit of 484 million yuan, up 16.36% [5][6] - The net profit excluding non-recurring items was 466 million yuan, showing an 8.16% increase [5][6] - Basic earnings per share rose to 0.64 yuan, a 16.36% increase from the previous year [6] Group 3 - Ruida New Materials reported a revenue of 975 million yuan, a decline of 7.36% year-on-year, with a net profit of 82 million yuan, down 24.19% [7][8] - The net profit excluding non-recurring items was 79 million yuan, reflecting a decrease of 27.57% [7][8] - The company experienced a negative cash flow from operating activities of 80 million yuan [8] Group 4 - Yongtai Technology reported a revenue of 2.61 billion yuan, a year-on-year increase of 21.97%, with a net profit of 59 million yuan, up 56.17% [10][11] - The net profit excluding non-recurring items was 23 million yuan, down 15.08% [10][11] - Basic earnings per share increased to 0.06 yuan, a 50% rise compared to the previous year [11] Group 5 - Shida Shenghua reported a revenue of 3.01 billion yuan, a year-on-year increase of 14.87%, but a net loss of 56 million yuan, a decline of 248.03% [13][14] - The net loss excluding non-recurring items was 57 million yuan, down 282.11% [13][14] - The company reported a positive cash flow from operating activities of 90 million yuan [14] Group 6 - Duofluor reported a revenue of 4.33 billion yuan, a decline of 6.65% year-on-year, with a net profit of 51 million yuan, down 16.55% [15][16] - The net profit excluding non-recurring items was a loss of 4.81 million yuan, reflecting a decrease of 179.71% [15][16] - Basic earnings per share decreased to 0.0441 yuan, down 15.19% [16] Group 7 - Tianji Co. reported a revenue of 1.07 billion yuan, a year-on-year increase of 19.16%, but a net loss of 52 million yuan, an improvement of 59% compared to the previous year [18][19] - The net loss excluding non-recurring items was 56 million yuan, down 56.04% [18][19] - The company reported a negative cash flow from operating activities of 131 million yuan [19] Group 8 - Huayu Pharmaceutical reported a revenue of 882 million yuan, a decline of 1.73% year-on-year, with a net loss of 5.81 million yuan, a decline of 116.23% [21][22] - The net loss excluding non-recurring items was 21.59 million yuan, down 247.06% [21][22] - The company reported a negative cash flow from operating activities of 169 million yuan [22] Group 9 - Haike New Source reported a revenue of 2.32 billion yuan, a year-on-year increase of 27.92%, but a net loss of 42 million yuan, an improvement of 61.21% [23][24] - The net loss excluding non-recurring items was 49 million yuan, down 56.57% [23][24] - The company reported a negative cash flow from operating activities of 248 million yuan [24] Group 10 - Hualu Hengsheng reported a revenue of 15.76 billion yuan, a decline of 7.14% year-on-year, with a net profit of 1.57 billion yuan, down 29.47% [26][27] - The net profit excluding non-recurring items was 1.56 billion yuan, reflecting a decrease of 30.29% [26][27] - Basic earnings per share decreased to 0.739 yuan, down 29.48% [27] Group 11 - Huasheng Lithium reported a revenue of 349 million yuan, a year-on-year increase of 72.02%, but a net loss of 72 million yuan [29] - The net profit excluding non-recurring items was a loss of 78 million yuan [29] - The company reported a negative cash flow from operating activities of 183 million yuan [29] Group 12 - Fuxiang Pharmaceutical reported a revenue of 514 million yuan, a decline of 24.58% year-on-year, with a net loss of 6.91 million yuan, an increase of 69.23% [31][32] - The net loss excluding non-recurring items was 32 million yuan, reflecting a decrease of 34.91% [31][32] - The company reported a negative cash flow from operating activities of 10 million yuan [32] Group 13 - Furui Co. reported a revenue of 2.59 billion yuan, a decline of 3.03% year-on-year, but a net profit of 246 million yuan, an increase of 10.92% [34][35] - The net profit excluding non-recurring items was 250 million yuan, reflecting a growth of 15.71% [34][35] - The company reported a positive cash flow from operating activities of 447 million yuan [35] Group 14 - The overall performance of companies in the electrolyte and raw material sector has been poor, with most companies reporting unsatisfactory financial results [36] - Except for Tianqi and New Zobang, other companies in the electrolyte sector have shown average performance [36] - Companies in the lithium hexafluorophosphate sector have reported significant losses, with net profits declining across the board [36]